Netherlands Point of Care Diagnostics Market Overview, 2031

Key Insights

• The point-of-care (POC) testing sector is transitioning from traditional lateral flow immunochromatography toward microfluidic Lab-on-a-Chip platforms and rapid isothermal nucleic acid amplification testing (NAAT). Technological breakthroughs such as single-use microfluidic cartridges paired with rapid thermal amplification allow healthcare personnel to run multi-pathogen PCR panels at the bedside, delivering definitive genomic results for respiratory viruses, hospital-acquired infections, and sexually transmitted infections in under 20 minutes without central laboratory infrastructure.
• Hospital emergency rooms, intensive care units, and outpatient primary care clinics are increasingly embedding high-sensitivity POC analyzers into immediate clinical workflows. Advanced benchtop analyzers measuring high-sensitivity cardiac troponin, C-reactive protein (CRP), and arterial blood gases enable immediate risk stratification for patients exhibiting acute coronary syndrome or sepsis. This shift significantly reduces emergency department wait times, accelerates targeted antibiotic administration, and relieves burden on central pathology departments.
• Point-of-care hardware is evolving from standalone diagnostic readers to cloud-connected diagnostic nodes. Breakthroughs in Bluetooth-enabled electrochemical biosensors and continuous glucose monitoring (CGM) systems allow patient metrics to synchronize automatically with hospital Electronic Health Records (EHR) and remote monitoring platforms. This automated connectivity eliminates pre-analytical recording errors, optimizes clinical trial data collection, and enables virtual care teams to make real-time therapeutic adjustments.

Market Outlook

• The point-of-care diagnostics market is set for structural expansion driven by the global transition toward decentralized healthcare models and home-based patient management. As health systems address aging populations and rising chronic disease burdens, regulatory frameworks are creating accelerated pathways for CLIA-waived, OTC, and user-friendly diagnostic devices. The expansion of retail pharmacy diagnostic screening services (TROD protocols) and direct-to-consumer digital health kits will continue to shift routine diagnostic volume away from centralized hospitals toward primary care practices, community clinics, and home health settings.
• Major commercial developers operating in the point-of-care diagnostics sector include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation (Cepheid), Siemens Healthineers, BD (Becton, Dickinson and Company), bioMérieux, QuidelOrtho, QIAGEN, and Sysmex Corporation, operating under regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA / EU IVDR), and guided by professional organizations like the Association for Diagnostics & Laboratory Medicine (ADLM).

Market Dynamics

Driver: Rising burden of infectious and chronic diseases
The healthcare ecosystem faces an accelerating prevalence of chronic lifestyle disorders (such as diabetes and cardiovascular conditions) alongside recurring outbreaks of infectious pathogens (including respiratory viruses and drug-resistant strains). This high disease volume creates an urgent, continuous clinical demand for rapid, decentralized testing solutions that bypass central laboratory bottlenecks, shorten turnaround times, and prompt immediate therapeutic decisions.
Challenge: Strict regulatory hurdles and quality control inconsistencies
Commercializing and deploying POC diagnostics globally requires navigating stringent, multi-region regulatory frameworks (such as FDA clearances, CE-IVDR compliance, and national health authority registrations). Furthermore, operating decentralized tests outside traditional laboratory walls introduces risks of operator error, calibration drift, and inconsistent quality control compliance across multi-site care environments.
Trend: Integration of digital health, connectivity, and multiplexing
The market is rapidly pivoting toward smart, pocket-sized diagnostic platforms embedded with Bluetooth, IoT, and cloud connectivity. These connected tools allow real-time test data to sync directly into electronic health records (EHRs) while utilizing advanced multiplex cartridges capable of detecting multiple pathogens or biomarkers from a single patient sample.

Segment Analysis

Point of Care Diagnostics By Product
• Glucose monitoring kits are evolving from basic finger-stick meters into broader diabetes-management ecosystems that combine meters, disposable strips, lancets, connectivity, and increasingly automated data capture. The distinctive product opportunity lies in reducing the number of user actions required between sampling and recording a result, while connected systems can make repeated readings more useful for longitudinal disease management.
• Infectious-disease POC kits are differentiated by how much of the diagnostic pathway they can move outside the central laboratory. Rapid antigen and serology formats prioritize simplicity and immediate screening, while molecular kits increasingly integrate specimen preparation, amplification, detection, and interpretation within a compact system. This creates opportunities for multiplex testing and syndromic panels, particularly where identifying a specific pathogen can alter treatment or infection-control decisions.
• Pregnancy and fertility testing kits are among the most naturally decentralized diagnostic products because testing can be performed privately using relatively simple specimens and procedures. Beyond conventional pregnancy tests, the segment includes ovulation-prediction and fertility-window products that transform testing from a single result into repeated cycle monitoring. Product differentiation increasingly centers on clearer result interpretation, digital readers, smartphone-assisted tracking, and designs that minimize user error.
• Hematology POC kits bring selected blood-cell and coagulation measurements closer to the patient through compact analyzers, cartridges, and simplified sample-processing workflows. The category is moving beyond individual hemoglobin measurements toward platforms capable of providing broader hematological information with minimal manual intervention. Automated sample handling and integrated quality controls are particularly valuable because decentralized hematology testing must reduce operator-dependent variability while maintaining clinically interpretable results.
• Cardiometabolic monitoring kits increasingly combine several measurements associated with chronic-disease management rather than treating each biomarker independently. Glucose, HbA1c, lipid parameters, ketones, and related measurements can be incorporated into connected monitoring workflows, allowing individual readings to become part of a longer-term patient record. The distinctive direction is therefore toward interoperability, automated data transmission, and multi-analyte platforms.
• Urinalysis testing kits provide a particularly flexible POC format because one specimen can be screened for several biochemical characteristics using a single disposable strip or compact reader. Traditional visual dipsticks are increasingly complemented by automated readers that standardize color interpretation and electronically capture results. This creates a transition from simple screening tools toward structured diagnostic workflows in which urine findings can be automatically documented and flagged for follow-up.
• Cholesterol test strips connect home and near-patient testing with conventional lipid assessment by using small capillary-blood samples and compact analyzers. The category is increasingly moving toward simplified sampling and reader-based systems rather than relying exclusively on visually interpreted strips. Integration with broader cardiometabolic platforms is another differentiating feature, allowing cholesterol results to be considered alongside glucose and other risk-related measurements.
• Other Products encompass a diverse group of POC applications, including cardiac biomarkers, blood gases, electrolytes, coagulation, toxicology, thyroid testing, cancer-related markers, fecal occult blood testing, and specialized biomarkers. The distinctive feature of this segment is its role as an innovation platform: manufacturers can use modular analyzers and disposable cartridges to expand from one clinical application into multiple testing menus.



Point of Care Diagnostics By Technology/Platform
• Lateral flow assays remain a foundational POC technology because they can package sample movement, reagent interaction, and visual or instrument-assisted detection into a compact disposable format. Their major differentiator is operational simplicity: many applications can be performed with minimal equipment and limited technical training. The platform is particularly versatile across infectious diseases, pregnancy, fertility, and other rapid screening applications.
• Molecular POC platforms are increasingly designed as integrated sample-to-answer systems rather than miniature versions of conventional PCR laboratories. Cartridge architectures can combine specimen preparation, nucleic-acid extraction, amplification, detection, and result interpretation, reducing manual handling and contamination opportunities. Isothermal amplification can offer another route to decentralized molecular testing where conventional thermal cycling would be impractical.
• Microfluidics and immunoassays enable complex laboratory processes to be miniaturized into cartridges and compact instruments. Microfluidic architectures can precisely control very small sample volumes and integrate preparation, reaction, separation, and detection, while immunoassays are suitable for proteins, hormones, antigens, antibodies, and other biomarkers. Their unique value is the potential to deliver several laboratory functions within a controlled disposable workflow.
• Dipsticks and test strips remain important because they offer an exceptionally simple path from specimen collection to an interpretable result. Their applications span glucose, urine chemistry, pregnancy, fertility, and cholesterol testing, while reader-assisted versions can automate interpretation and digitally record findings. A key technological transition is therefore from purely visual strips toward strip-and-reader ecosystems, where software can reduce subjective interpretation and connect results to electronic records.

Point of Care Diagnostics By End-User
• Hospitals and critical-care centers use POC diagnostics where immediate test information can complement centralized laboratory services, particularly in emergency, intensive-care, surgical, and other time-sensitive environments. The defining feature of this segment is workflow integration: POC results must fit into clinical decision-making, quality-control procedures, operator training, and patient records rather than functioning as isolated measurements.
• Clinical and diagnostic laboratories increasingly serve as the quality-management backbone for distributed POC testing. Their role can include method verification, quality control, calibration, operator competency, troubleshooting, result review, and confirmation of selected findings. Consequently, POC does not simply replace centralized laboratories; it redistributes portions of testing while increasing the importance of governance across multiple testing locations.
• Home care and self-testing are transforming POC diagnostics from an episodic clinical service into a continuous consumer-health activity. Glucose, pregnancy, fertility, cholesterol, and selected infectious-disease tests can be performed without a conventional laboratory visit, while connected devices can transmit readings into digital health or remote-monitoring workflows. The defining product challenge is balancing analytical reliability with consumer simplicity: sampling, timing, interpretation, error handling, and result communication all have to work without a laboratory professional physically present.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Point of Care Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Glucose Monitoring Kits
• Infectious Diseases Testing Kits
• Pregnancy And Fertility Testing Kits
• Hematology Testing Kits
• Cardiometabolic Monitoring Kits
• Urinalysis Testing Kits
• Cholesterol Test Strips
• Other Products

By Technology/Platform
• Lateral Flow Assays
• Molecular Diagnostics (PCR/INAAT)
• Microfluidics & Immunoassays
• Dipsticks & Test Strips

By End-User
• Hospitals & Critical Care Centers
• Clinical & Diagnostic Laboratories
• Home Care & Self-Testing

By Mode Of Purchase
• Prescription Based Products
• OTC Products

By Sample
• Blood
• Urine
• Nasal and Oropharyngeal Swabs